Future Directions: Targeting LAG-3 in Melanoma Treatment
Host: Hussein Tawbi, MD, PhD
\n\n\n \n
This activity focuses on improving clinician awareness and knowledge of LAG-3-based immunotherapy in metastatic melanoma. We aim to identify patients with metastatic melanoma who can benefit from LAG-3/PD-1 combination therapy and enhance the competence of the multidisciplinary team in managing these patients.